Effect of resiquimod 0.01% gel on lesion healing and viral shedding when applied to genital herpes lesions

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 2, 2008, Pages 477-482

  Fife, Kenneth H ^a   Meng, Tze Chiang ^b   Ferris, Daron G ^c   Liu, Ping ^b,d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b 3M COMPANY   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; RESIQUIMOD; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; VIRUS DNA;

ADULT; AGED; APPLICATION SITE BURNING; ARTICLE; BEDTIME DOSAGE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GEL; GENITAL HERPES; HEADACHE; HERPES SIMPLEX VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RESPIRATORY TRACT DISEASE; SCORING SYSTEM; SKIN DISEASE; SKIN FISSURE; SYMPTOMATOLOGY; THORAX DISEASE; TREATMENT OUTCOME; VIRUS SHEDDING; WOUND HEALING;

ADMINISTRATION, TOPICAL; ADULT; AGED; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; TIME FACTORS; TREATMENT OUTCOME; VIRUS SHEDDING; WOUND HEALING;

EID: 38649143209     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01173-07     Document Type: Article

References (25)

1. Ahonen, C. L., S. J. Gibson, R. M. Smith, L. K. Pederson, J. M. Lindh, M. A. Tomai, and J. P. Vasilakos. 1999. Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848. Cell. Immunol. 197:62-72.
2. Alrabiah, F. A., and S. L. Sacks. 1996. New antiherpesvirus agents: their targets and therapeutic potential. Drugs 52:17-32.
3. Bernstein, D. I., C. J. Harrison, M. A. Tomai, and R. L. Miller. 2001. Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment. J. Infect. Dis. 183:844-849.
4. Burns, R. P., Jr., B. Ferbel, M. Tomai, R. Miller, and A. A. Gaspari. 2000. The imidazoquinolines, imiquimod, and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clin. Immunol. 94:13-23.
5. Corey, L., A. Mindel, K. H. Fife, S. Sutherland, J. Benedetti, and M. W. Adler. 1985. Risk of recurrence after treatment of first-episode genital herpes with intravenous acyclovir. Sex. Transm. Dis. 12:215-218.
6. Douglas, J. M., C. Critchlow, J. Benedetti, G. J. Mertz, J. D. Connor, M. A. Hintz, A. Fahnlander, M. Remington, C. Winter, and L. Corey. 1984. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N. Engl. J. Med. 310:1551-1556.
7. Fife, K. H., C. S. Crumpacker, G. J. Mertz, E. L. Hill, and G. S. Boone. 1994. Recurrence and resistance patterns of herpes simplex virus following cessation of ≥6 years of chronic acyclovir suppression. J. Infect. Dis. 169:1338-1341.
8. Grambsch, P. M., and T. M. Therneau. 1994. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:515-526.
9. Harrison, C. J., L. Jenski, T. Voychehovski, and D. I. Bernstein. 1988. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antivir. Res. 10:209-223.
10. Harrison, C. J., R. L. Miller, and D. I. Bernstein. 1994. Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicrob. Agents Chemother. 38:2059-2064.
11. Hemmi, H., T. Kaisho, O. Takeuchi, S. Sato, H. Sanjo, K. Hoshino, T. Horiuchi, H. Tomizawa, K. Takeda, and S. Akira. 2002. Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3:196-200.
12. Jurk, M., F. Heil, J. Vollmer, C. Schetter, A. M. Krieg, H. Wagner, G. Lipford, and S. Bauer. 2002. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol. 3:499.
13. Mark, K. E., L. Corey, T. C. Meng, A. S. Magaret, M. L. Huang, S. Selke, H. B. Slade, S. K. Tyring, T. Warren, S. L. Sacks, P. Leone, V. A. Bergland, and A. Wald. 2007. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J. Infect. Dis. 195:1324-1331.
14. Mark, K. E., S. Spruance, G. R. Kinghorn, S. L. Sacks, H. B. Slade, T. C. Meng, S. Selke, and A. Wald. 2007. Three phase III randomized controlled trials of topical resiquimod gel 0.01% to prevent genital herpes recurrences, abstr. P-256. Abstr. 17th Int. Soc. Sex. Transm. Dis. Res. ISSTDR, Seattle, WA.
15. Mertz, G. J., C. W. Critchlow, J. Benedetti, R. C. Reichman, R. Dolin, J. Connor, D. C. Redfield, M. C. Savoia, D. D. Richman, D. L. Tyrrell, L. Miedzinski, J. Portnoy, R. E. Keeney, and L. Corey. 1984. Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection. JAMA 252:1147-1151.
16. Perry, C. M., and A. J. Wagstaff. 1995. Famciclovir: a review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs 50:396-415.
17. Reichman, R. C., G. J. Badger, G. J. Mertz, L. Corey, D. D. Richman, J. D. Connor, D. Redfield, M. C. Savoia, M. N. Oxman, Y. Bryson, D. L. Tyrrell, J. Portnoy, T. Creigh-Kirk, R. E. Keeney, T. Ashikaga, and R. Dolin. 1984. Treatment of recurrent genital herpes simplex infections with oral acyclovir. JAMA 251:2103-2107.
18. Sauder, D. N., M. H. Smith, T. Senta-McMillian, I. Soria, and T. C. Meng. 2003. Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults. Antimicrob. Agents Chemother. 47:3846-3852.
19. Spruance, S. L., S. K. Tyring, M. H. Smith, and T. C. Meng. 2001. Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. J. Infect. Dis. 184:196-200.
20. Straus, S. E., H. E. Takiff, M. Seidlin, S. Bachrach, L. Lininger, J. J. DiGiovanna, K. A. Western, H. A. Smith, S. Nusinoff Lehrman, T. Creagh-Kirk, and D. W. Alling. 1984. Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir. N. Engl. J. Med. 310:1545-1550.
21. Tomai, M. A., S. J. Gibson, L. M. Imbertson, R. L. Miller, P. E. Myhre, M. J. Reiter, T. L. Wagner, C. B. Tamulinas, J. M. Beaurline, J. F. Gerster, and V. L. Horton. 1995. Immunomodulating and antiviral activities of the imidazoquinoline S-28463. Antivir. Res. 28:253-264.
22. Wagner, T. L., C. L. Ahonen, A. M. Couture, S. J. Gibson, R. L. Miller, R. M. Smith, M. J. Reiter, J. P. Vasilakos, and M. A. Tomai. 1999. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell. Immunol. 191:10-19.
23. Wald, A., L. Corey, R. Cone, A. Hobson, G. Davis, and J. Zeh. 1997. Frequent genital herpes simplex virus 2 shedding in immunocompetent women: effect of acyclovir treatment. J. Clin. Investig. 99:1092-1097.
24. Whitley, R. J., and J. W. Gnann, Jr. 1992. Acyclovir: a decade later. N. Engl. J. Med. 327:782-789.
25. Xu, F., M. R. Sternberg, B. J. Kottiri, G. M. McQuillan, F. K. Lee, A. J. Nahmias, S. M. Berman, and L. E. Markowitz. 2006. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296:964-973.